SLAMF7

SLAMF7

SLAMF7 Informations sur la molécule

Molecule Name
SLAM family member 7
Alias de la molécule
SLAMF7,CD319,CS1,CRACC,19A,FOAP-12
Drug Development Progress
Nombre de médicaments cliniques8
Nombre de médicaments commercialisés1
Phase de R&D la plus avancéeApproved
Alias de la cible
CS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,CD319 Antigen,Novel LY9 (Lymphocyte Antigen 9) Like Protein
Contexte de la molécule
SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7 Liste de produits

Species
  • Human(6)
  • Mouse(1)
  • Rhesus macaque(1)
Tag
  • His Tag(5)
  • Fc Tag(1)
  • His Tag & Avi Tag(1)
  • Mouse IgG Fc Tag(1)
Host
  • HEK293(8)
Conjugate
  • Unconjugated(4)
  • PE Labeled(2)
  • Biotin-labeled(1)
  • FITC Labeled(1)
Grade
  • RUO(8)
Low Endotoxin
  • Yes(2)
  • No(6)
You Have Viewed 1-8 Of 8 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital)Phase 2 ClinicalUniversity Hospital Würzburg
Multiple Myeloma
Details
dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology)Phase 1 ClinicalWuhan Sian Biotechnology Co Ltd
Multiple Myeloma
Details
BCMA-CS1 cCAR T-cell therapyPhase 1 ClinicaliCell Gene Therapeutics LLC
Multiple Myeloma
Details
SA102-CAR-TSA-102; SA102Phase 1 ClinicalWuhan Sian Biotechnology Co Ltd
Multiple Myeloma
Details
WS-CART-CS1WS-CART-CS1Phase 1 ClinicalPaula C. & Rodger O. Riney Blood Cancer Research, Washington University School Of Medicine
Multiple Myeloma
Details
MB-104MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CARPhase 1 ClinicalCity Of Hope National Medical Center
Glioblastoma; Multiple Myeloma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
CS1 Targeted CAR T-cells (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd
Multiple Myeloma
Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology)ClinicalWuhan BioRaid Biotechnology Co Ltd
Hematologic Neoplasms
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
ElotuzumabPDL-063; HuLuc-63; BMS-901608ApprovedAbbvie Inc, Bristol-Myers Squibb CompanyEmplicitiUnited StatesMultiple MyelomaBristol-Myers Squibb Company2015-11-30
Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia, Plasma Cell; Lymphoma; Multiple Myeloma; Polycythemia Vera; Primary Myelofibrosis; Smoldering Multiple Myeloma; Thrombocythemia, Essential
Details
Customer Reviews